The FTO gene variant (rs9939609) influences not just hunger but also circadian rhythm sensitivity, meaning some patients benefit more dramatically from GLP-1's sleep-regulating effects while others experience a gentler transition
This shift reflects growing recognition of GLP-1 agonists as effective weight loss tools independent of diabetes status
It replenishes the lipids within the skin, nourishes the skins structural integrity and potentially improves the appearance of red and irritated skin
But the most important metrics for employers are: Clinical outcomes % weight loss at 3, 6, 12 months Improvements in blood pressure, HbA1c, cholesterol (where available) Medication usage trends Average GLP-1 dose per member Time on medication Escalation and tapering rates Behavior change engagement Weekly coaching session attendance Improvements in sleep, nutrition, movement, stress Financial impact Changes in obesity-related claims (e.g
Grx2 - / - hearts also developed left ventricular hypertrophy and fibrosis and mice developed hypertension